8V6 Stock Overview
Offers cancer care and pain management solutions in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Scandinavian ChemoTech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.10 |
| 52 Week High | SEK 0.30 |
| 52 Week Low | SEK 0.093 |
| Beta | 1.37 |
| 11 Month Change | -15.77% |
| 3 Month Change | -15.42% |
| 1 Year Change | -45.72% |
| 33 Year Change | -94.24% |
| 5 Year Change | n/a |
| Change since IPO | -91.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8V6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -15.8% | 2.9% | 0.8% |
| 1Y | -45.7% | -4.7% | 8.6% |
Return vs Industry: 8V6 underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: 8V6 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 8V6 volatility | |
|---|---|
| 8V6 Average Weekly Movement | 22.0% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8V6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8V6's weekly volatility has decreased from 27% to 22% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 5 | Stefan Frick | chemotech.se |
Scandinavian ChemoTech AB (publ) offers cancer care and pain management solutions in Sweden. The company offers IQWave, an electroporation device, used for electrochemotherapy and treatment of head and neck cancer, squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. It also offers Vetiqure for the treatment of superficial tumors in dogs, cats, and horses.
Scandinavian ChemoTech AB (publ) Fundamentals Summary
| 8V6 fundamental statistics | |
|---|---|
| Market cap | €3.50m |
| Earnings (TTM) | -€1.36m |
| Revenue (TTM) | €436.71k |
8.0x
P/S Ratio-2.6x
P/E RatioIs 8V6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8V6 income statement (TTM) | |
|---|---|
| Revenue | SEK 5.03m |
| Cost of Revenue | SEK 2.02m |
| Gross Profit | SEK 3.01m |
| Other Expenses | SEK 18.71m |
| Earnings | -SEK 15.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 04, 2025
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 59.88% |
| Net Profit Margin | -311.96% |
| Debt/Equity Ratio | 0% |
How did 8V6 perform over the long term?
See historical performance and comparison